Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma

Annals of the Academy of Medicine Singapore

Volumn 42, Issue 6, 2013, Pages 291-296

  Tan, Grace Hc ^a   Cheung, Michelle ^a   Chanyaputhipong, Jendana ^a   Soo, Khee Chee ^a,b   Teo, Melissa C C ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Intraoperative chemotherapy; Mesotheliomas; Peritonectomy

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; PACLITAXEL; TUMOR MARKER;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADJUVANT CHEMOTHERAPY; ADULT; APPENDECTOMY; ARTICLE; CANCER CHEMOTHERAPY; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYSTERECTOMY; INTESTINE RESECTION; KIDNEY CARCINOMA; LAPAROTOMY; MALE; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVERALL SURVIVAL; PERITONEUM; PERITONEUM MESOTHELIOMA; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; SALPINGOOOPHORECTOMY; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84879673425     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-7
2. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839-49
3. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol 2008;9:147-57
4. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008;132:397-401
5. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyoxma peritonei syndrome. Adv Surg 1996;30:233-80
6. Sugarbaker PH, editor. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic, 1996
7. Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermicintraperitoneal chemotherapy. Cancer Treat Rev 2001;27:365-74
8. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the effi cacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007;18:827-34
9. Sugarbaker PH, Acherman YIZ, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, et al. Diagnosis and treatment of peritoneal mesothelioma: Washington Cancer Institute experience. Semin Oncol 2002;29:51-61
10. Sugarbaker PH, Welch LS, Mohamed F. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clinic N Am 2003;12:605-21
11. Butterworth SA, Panton ONM, Klaassen DJ, Shah AM, McGregor GI. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg 2002;183:529-32
12. Ahmad SA, Kim J, Sussman JJ, Soldano DA, Soldano DA, Pennington LJ, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004;11:387-92
13. M Teo, KF Foo, WH Koo, Wong LT, Soo KC. Lessons learned from initial experience with peritonectomy and intra-peritoneal chemotherapy infusion. World J Surg 2006;30:12,2132-5
14. Chua TC, Yan TD, Morris DL. Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg 2009;52:59-64
15. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM, et al. Diffuse malignant mesothelioma. Ann Intern Med 1982;96:746-755
16. Maurer R, Egloff B. Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 1975;36:1381-5
17. Huncharek M. Non-asbestos related diffuse malignant mesothelioma. Tumori 2002;88:1-9
18. Yu W, Chan-On W, Teo M, Ong CK, Cutcutache I, Allen GE, et al. First somaticmutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biol 2011;12:R96
19. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesotheioma treated with cytoreductive surgery and intra-peritoneal hyperthermic perfusion. Ann Surg Oncol 2006;13:229-37
20. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70:6-12
21. Bagia M, Nowak AK. Novel targeted therapies and vaccination strategies for mesothelioma. Curr Treat Options Onco 2011;12:149-62
22. Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summaryof the fi rst NIH peritoneal mesothelioma conference. Ann Oncol 2006;17:1615-9
23. Zaffaroni N, Costa A, Pennati M, De Marco C, Affi ni E, Madeo M, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 2007;29:453-66